PE20212090A1 - Inhibidores aza-heterobiciclicos de mat2a y metodos de uso para tratar el cancer - Google Patents
Inhibidores aza-heterobiciclicos de mat2a y metodos de uso para tratar el cancerInfo
- Publication number
- PE20212090A1 PE20212090A1 PE2021001086A PE2021001086A PE20212090A1 PE 20212090 A1 PE20212090 A1 PE 20212090A1 PE 2021001086 A PE2021001086 A PE 2021001086A PE 2021001086 A PE2021001086 A PE 2021001086A PE 20212090 A1 PE20212090 A1 PE 20212090A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- heterobycyclic
- aza
- methods
- treat cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Esta referido a compuestos de formula I, en donde: L es O, S, NR o un enlace; R1 es alquilo, alquenilo, carbociclilo, entre otros; R2 y R3 son alquinilo, arilo, carbociclilo, entre otros; R4 es H, alquilo, OH, halo, entre otros; R5 es H, alquilo, alcoxi, alquenilo, entre otros. Entre los compuestos preferidos tenemos los siguientes: 6-etoxi-2-(2-metil-2H-indazol-5-il)-4- (4-(trifluorometoxi)fenil)pirido[3,2- c]piridazin-3(2H)-ona; 6-(2,2-difluoroetoxi)-4-(4- (difluorometoxi)fenil)-2-(4- metoxifenil)pirido[3,2-c]piridazin3(2H)-ona; entre otros. Estos compuestos son inhibidores de la isoforma 2A de metionina adenosiltransferasa (MAT2A) y se emplean en el tratamiento de diversos tipos de cancer, lo que incluye algunos canceres en los que se elimina el gen que codifica la metiltioadenosina fosforilasa (MTAP).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785519P | 2018-12-27 | 2018-12-27 | |
| PCT/US2019/068652 WO2020139991A1 (en) | 2018-12-27 | 2019-12-27 | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20212090A1 true PE20212090A1 (es) | 2021-11-04 |
Family
ID=69400625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001086A PE20212090A1 (es) | 2018-12-27 | 2019-12-27 | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso para tratar el cancer |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US20220144820A1 (es) |
| EP (1) | EP3902803B1 (es) |
| JP (2) | JP7418441B2 (es) |
| KR (1) | KR20220051301A (es) |
| CN (1) | CN113454085B (es) |
| AR (1) | AR117544A1 (es) |
| AU (1) | AU2019416349B2 (es) |
| BR (1) | BR112021012595A2 (es) |
| CA (1) | CA3124952A1 (es) |
| CL (1) | CL2021001721A1 (es) |
| CO (1) | CO2021009879A2 (es) |
| CR (1) | CR20210410A (es) |
| DK (1) | DK3902803T3 (es) |
| EA (1) | EA202191801A1 (es) |
| ES (1) | ES2942310T3 (es) |
| FI (1) | FI3902803T3 (es) |
| GE (1) | GEP20237519B (es) |
| HR (1) | HRP20230161T1 (es) |
| HU (1) | HUE061834T2 (es) |
| IL (1) | IL284326B1 (es) |
| JO (1) | JOP20210172A1 (es) |
| LT (1) | LT3902803T (es) |
| MA (1) | MA54608B1 (es) |
| MD (1) | MD3902803T2 (es) |
| MX (1) | MX2021007829A (es) |
| PE (1) | PE20212090A1 (es) |
| PL (1) | PL3902803T3 (es) |
| PT (1) | PT3902803T (es) |
| RS (1) | RS64135B1 (es) |
| SG (1) | SG11202106637SA (es) |
| SI (1) | SI3902803T1 (es) |
| TW (1) | TWI816962B (es) |
| UA (1) | UA127525C2 (es) |
| WO (1) | WO2020139991A1 (es) |
| ZA (1) | ZA202104423B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202105469YA (en) | 2018-12-10 | 2021-06-29 | Ideaya Biosciences Inc | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| KR20230094196A (ko) * | 2020-07-31 | 2023-06-27 | 탱고 테라퓨틱스, 인크. | Mtap-결핍 및/또는 mta 축적 암의 치료에 유용한 피페리딘-1-일-n-피리딘-3-일-2-옥소아세트아마이드 유도체 |
| WO2022052924A1 (zh) * | 2020-09-11 | 2022-03-17 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
| WO2022206730A1 (zh) * | 2021-03-29 | 2022-10-06 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| WO2022253242A1 (zh) * | 2021-06-02 | 2022-12-08 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a抑制剂 |
| US20230192679A1 (en) * | 2021-12-17 | 2023-06-22 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
| WO2023116696A1 (zh) * | 2021-12-21 | 2023-06-29 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a的杂环抑制剂 |
| TW202342024A (zh) * | 2022-03-11 | 2023-11-01 | 大陸商賽諾哈勃藥業（成都）有限公司 | 甲硫胺酸腺苷轉移酶抑制劑、其藥物組合物及應用 |
| WO2024080788A1 (ko) | 2022-10-13 | 2024-04-18 | 한미약품 주식회사 | 신규한 트리사이클 유도체 화합물 및 이의 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| CA2422371C (en) | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2017319500C1 (en) * | 2016-08-31 | 2022-10-20 | Les Laboratoires Servier | Inhibitors of cellular metabolic processes |
| PE20200342A1 (es) | 2017-05-22 | 2020-02-14 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue |
| CN111936499B (zh) * | 2018-03-30 | 2023-09-19 | 法国施维雅药厂 | Mat2a的杂二环抑制剂和用于治疗癌症的方法 |
-
2019
- 2019-12-27 WO PCT/US2019/068652 patent/WO2020139991A1/en active Application Filing
- 2019-12-27 DK DK19845796.2T patent/DK3902803T3/da active
- 2019-12-27 SG SG11202106637SA patent/SG11202106637SA/en unknown
- 2019-12-27 LT LTEPPCT/US2019/068652T patent/LT3902803T/lt unknown
- 2019-12-27 MA MA54608A patent/MA54608B1/fr unknown
- 2019-12-27 GE GEAP201915703A patent/GEP20237519B/en unknown
- 2019-12-27 EA EA202191801A patent/EA202191801A1/ru unknown
- 2019-12-27 PE PE2021001086A patent/PE20212090A1/es unknown
- 2019-12-27 MD MDE20211082T patent/MD3902803T2/ro unknown
- 2019-12-27 US US17/418,442 patent/US20220144820A1/en active Pending
- 2019-12-27 KR KR1020217023828A patent/KR20220051301A/ko unknown
- 2019-12-27 EP EP19845796.2A patent/EP3902803B1/en active Active
- 2019-12-27 IL IL284326A patent/IL284326B1/en unknown
- 2019-12-27 BR BR112021012595-7A patent/BR112021012595A2/pt unknown
- 2019-12-27 AR ARP190103903A patent/AR117544A1/es unknown
- 2019-12-27 HU HUE19845796A patent/HUE061834T2/hu unknown
- 2019-12-27 JO JOP/2021/0172A patent/JOP20210172A1/ar unknown
- 2019-12-27 TW TW108148216A patent/TWI816962B/zh active
- 2019-12-27 CR CR20210410A patent/CR20210410A/es unknown
- 2019-12-27 SI SI201930515T patent/SI3902803T1/sl unknown
- 2019-12-27 CN CN201980092742.2A patent/CN113454085B/zh active Active
- 2019-12-27 UA UAA202104321A patent/UA127525C2/uk unknown
- 2019-12-27 FI FIEP19845796.2T patent/FI3902803T3/fi active
- 2019-12-27 PT PT198457962T patent/PT3902803T/pt unknown
- 2019-12-27 RS RS20230240A patent/RS64135B1/sr unknown
- 2019-12-27 MX MX2021007829A patent/MX2021007829A/es unknown
- 2019-12-27 ES ES19845796T patent/ES2942310T3/es active Active
- 2019-12-27 JP JP2021538127A patent/JP7418441B2/ja active Active
- 2019-12-27 HR HRP20230161TT patent/HRP20230161T1/hr unknown
- 2019-12-27 CA CA3124952A patent/CA3124952A1/en active Pending
- 2019-12-27 PL PL19845796.2T patent/PL3902803T3/pl unknown
- 2019-12-27 AU AU2019416349A patent/AU2019416349B2/en active Active
-
2021
- 2021-06-25 ZA ZA2021/04423A patent/ZA202104423B/en unknown
- 2021-06-25 CL CL2021001721A patent/CL2021001721A1/es unknown
- 2021-07-27 CO CONC2021/0009879A patent/CO2021009879A2/es unknown
-
2023
- 2023-12-11 JP JP2023208546A patent/JP2024015340A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20212090A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso para tratar el cancer | |
| PE20211411A1 (es) | Compuestos de anillo fusionado | |
| PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| BRPI0413255A (pt) | uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer | |
| PE20170403A1 (es) | COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER | |
| PA8537501A1 (es) | Naftostirilos | |
| MEP52808A (en) | Aminoheteroaryl compounds as protein kinase inhibitors | |
| PE20151981A1 (es) | Pontenciador de inhibidores del homologo de zeste | |
| ECSP045253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| CL2021001722A1 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
| PE20060185A1 (es) | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA | |
| NI200500174A (es) | Beta-carboniles útiles para el tratamiento de enfermedades inflamatorias | |
| GEP20125368B (en) | Kinase inhibitors | |
| PE20071138A1 (es) | Derivados de pirimidina como inhibidores de quinasas | |
| DE602005026509D1 (de) | Hemmer der akt aktivität | |
| UY30942A1 (es) | Nuevos derivados de 3-([1,2,4,]triazolo[4,3-a]piridin-7-il)benzamida | |
| BR9909808A (pt) | Pirazolopirimidinonas inibidoras de cgmp pde5 para o tratamento da disfunção sexual | |
| CR7899A (es) | Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa | |
| MX2009012066A (es) | Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k. | |
| PE20070517A1 (es) | Derivados de imidazol como agentes inhibidores de la sintasa de aldosterona y aromatasa | |
| MA50655B1 (fr) | Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam | |
| ATE461179T1 (de) | Hemmer der akt aktivität | |
| EA200801996A1 (ru) | 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов | |
| TNSN08227A1 (en) | [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases. | |
| CL2008002398A1 (es) | Compuestos derivados de 6-(fenil piperidina) pirimidinas fusionadas con imidazol, triazol o pirozol, inhibidores de la via pi3k/akt; composicion farmaceutica; combinacion farmaceutica; y uso de los compuestos para el tratamiento de la neoplasia benigna y/o maligna y para el cancer. |